[Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois
B
B
Fédération de Neurologie, INSERM U289, Hôpital Pitié-Salpêtrière, Paris.
Montastruc
J L
JL
D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D012642:Selegiline / Q000009:adverse effects* / Q000627:therapeutic use
D000978:Antiparkinson Agents; D012642:Selegiline; D007980:Levodopa
Association lévodopa+sélégiline et augmentation du risque de mortalité dans le traitement de la maladie de Parkinson.